Erythropoiesis and Erythropoietin in Multiple Myeloma
- 1 January 1995
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 18 (5-6) , 413-421
- https://doi.org/10.3109/10428199509059639
Abstract
In this review, the pathophysiology and treatment of the anemia of multiple myeloma will be examined. While the anemia of cancer has multiple causes, an important component is labeled the “anemia of chronic disease” which is characterized by the combination of a shortened erythrocyte survival with failure of the bone marrow to increase red cell production in compensation. Depressed erythropoiesis is itself related to a combination of factors, including impaired availability of storage iron, inadequate erythropoietin response to anemia, and overproduction of cytokines which are capable of inhibiting erythropoiesis. These cytokines are involved in the retention of iron in the reticuloendothelial system, gastrointestinal tract and hepatocytes, may interfere with erythropoietin production by the kidney, and may exert direct inhibitory effects on erythroid precursors. While overproduction of several such cytokines, including IL-6, IL-1 and TNF-a, has been definitely demonstrated in multiple myeloma patients, it is still unclear whether they are directly involved in the pathogenesis of this anemia which develops. Although several mechanisms, such as hemodilution, bleeding, and decreased red cell survival operate, the anemia is mostly caused by defective erythropoietic activity. This in turn is partly explained by inadequate erythropoietin (Epo) production even in some patients without renal impairment. Based on measurements of serum erythropoietin and transferrin receptor, the distinction between marrow unresponsiveness to normal Epo stimulation and deficient Epo production is important for the treatment of the anemia of multiple myeloma with recombinant human Epo. Higher doses would probably be necessary if adequate Epo production is present, whereas only replacement therapy with lower doses may be sufficient when Epo production has been shown to be inappropriate.Keywords
This publication has 111 references indexed in Scilit:
- Serum erythropoietin in patients with myelofibrosis with myeloid metaplasiaBritish Journal of Haematology, 1993
- Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneysLife Sciences, 1992
- Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free mediumClinical Immunology and Immunopathology, 1991
- Erythropoietin Treatment of Anemia Associated with Multiple MyelomaNew England Journal of Medicine, 1990
- Decreased Erythropoietin Response in Patients with the Anemia of CancerNew England Journal of Medicine, 1990
- Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell linesCancer, 1989
- Production of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma CellsNew England Journal of Medicine, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- Interrelationships between Blood Volume, Venous Haematocrit and Renal Failure in MyelomatosisScandinavian Journal of Haematology, 1978
- IRON ABSORPTION IN HYPOFERREMIA*The Lancet Healthy Longevity, 1965